Back to Journals » International Journal of Nanomedicine » Volume 9 » Issue 1

Effects of PEGylated lipid nanoparticles on the oral absorption of one BCS II drug: a mechanistic investigation

Authors Zhang XW, Chen GJ, Zhang TP, Ma ZG, Wu BJ

Received 27 August 2014

Accepted for publication 11 October 2014

Published 26 November 2014 Volume 2014:9(1) Pages 5503—5514

DOI https://doi.org/10.2147/IJN.S73340

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 5

Editor who approved publication: Dr Thomas J Webster

Xingwang Zhang,* Guijiang Chen,* Tianpeng Zhang, Zhiguo Ma, Baojian Wu

Division of Pharmaceutics, College of Pharmacy, Jinan University, Guangzhou, People’s Republic of China

*These authors contributed equally to this work

Abstract: Lipid nanocarriers are becoming a versatile platform for oral delivery of lipophilic drugs. In this article, we aimed to explore the gastrointestinal behaviors of lipid nanoparticles and the effect of PEGylation on oral absorption of fenofibrate (FN), a Biopharmaceutics Classification System (BCS) II model drug. FN-loaded PEGylated lipid nanoparticles (FN-PLNs) were prepared by the solvent-diffusion method and characterized by particle size distribution, morphology, Fourier transform infrared spectroscopy, and drug release. Lipolytic experiments were performed to assess the resistance of lipid nanoparticles against pancreatic lipase. Pharmacokinetics was evaluated in rats after oral administration of FN preparations. The obtained FN-PLNs were 186.7 nm in size with an entrapment efficiency of >95%. Compared to conventional lipid nanoparticles, PLNs exhibited slower drug release in the lipase-containing medium, strikingly reduced mucin binding, and suppressed lipolysis in vitro. Further, oral absorption of FN was significantly enhanced using PLNs with relative bioavailability of 123.9% and 157.0% to conventional lipid nanoparticles and a commercial formulation (Lipanthyl®), respectively. It was demonstrated that reduced mucin trapping, suppressed lipolysis, and/or improved mucosal permeability were responsible for increased oral absorption. These results facilitated a better understanding of the in vivo fate of lipid nanoparticles, and suggested the potential of PLNs as oral carriers of BCS II drugs.

Keywords: fenofibrate, lipid nanoparticles, PEGylation, oral bioavailability, absorption mechanism

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Readers of this article also read:

Fluorescent graphene quantum dots as traceable, pH-sensitive drug delivery systems

Qiu J, Zhang R, Li J, Sang Y, Tang W, Rivera Gil P, Liu H

International Journal of Nanomedicine 2015, 10:6709-6724

Published Date: 28 October 2015

Inhibition of various gram-positive and gram-negative bacteria growth on selenium nanoparticle coated paper towels

Wang Q, Larese-Casanova P, Webster TJ

International Journal of Nanomedicine 2015, 10:2885-2894

Published Date: 13 April 2015

Multifaceted prospects of nanocomposites for cardiovascular grafts and stents

Vellayappan MV, Balaji A, Subramanian AP, John AA, Jaganathan SK, Murugesan S, Supriyanto E, Yusof M

International Journal of Nanomedicine 2015, 10:2785-2803

Published Date: 7 April 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Synthesis, pharmacokinetics, and biological use of lysine-modified single-walled carbon nanotubes

Mulvey JJ, Feinberg EN, Alidori S, McDevitt MR, Heller DA, Scheinberg DA

International Journal of Nanomedicine 2014, 9:4245-4255

Published Date: 4 September 2014

Nanotechnology-based drug delivery systems for treatment of oral cancer: a review

Calixto G, Bernegossi J, Fonseca-Santos B, Chorilli M

International Journal of Nanomedicine 2014, 9:3719-3735

Published Date: 8 August 2014

Evaluating the potential of cubosomal nanoparticles for oral delivery of amphotericin B in treating fungal infection

Yang Z, Chen M, Yang M, Chen J, Fang W, Xu P

International Journal of Nanomedicine 2014, 9:327-336

Published Date: 6 January 2014

Erratum

Schuelert N, Russell FA, McDougall JJ

Orthopedic Research and Reviews 2011, 3:9-10

Published Date: 1 March 2011

Topical diclofenac in the treatment of osteoarthritis of the knee

Niklas Schuelert, Fiona A Russell, Jason J McDougall

Orthopedic Research and Reviews 2011, 3:1-8

Published Date: 6 February 2011